Aveksim's Rimantadinum

General characteristics. Structure:

Active ingredient: 50 mg of Rimantadinum.

Excipients: lactose (sugar milk), potato starch, calcium stearate, talc.

Rimantadinum is active concerning various influenza strains And.

Pharmacological properties:

Pharmacodynamics. Being the weak basis, Rimantadinum works due to increase рН the endosomes having a membrane of vacuoles which surround virus particles after their penetration into a cell. Prevention of an atsidifikation in these vacuoles blocks merge of a viral envelope to an endosome membrane, preventing, thus, transfer of virus genetic material to cell cytoplasm. Rimantadinum also oppresses an exit of virus particles from a cell, i.e. interrupts a transcription of a virus genome.

Pharmacokinetics. After intake Rimantadinum is almost completely soaked up in intestines. Absorption - slow. Communication with proteins of plasma - about 40%. Vd: adult - 17-25 l/kg, children - 289 l. Concentration in a nasal secret is 50% higher, than in plasma. Cmax of active ingredient in a blood plasma at a dose of 100 mg of 1 times/days - 181 ng/ml, at 100 mg of 2 times/days - 416 ng/ml. It is metabolized in a liver. T1/2 is 24-36 h; 75-85% of the accepted dose are removed by kidneys generally in the form of metabolites, 15% - in not changed look.

At a chronic renal failure of T1/2 increases twice. At persons with a renal failure and at elderly people can collect in toxic concentration if the dose is not adjusted in proportion to reduction of KK.

Indications to use:

— prevention and early treatment of flu A at adults and children starshe7 years.

Route of administration and doses:

Inside after food, washing down with water. Treatment of flu should be begun during 24-48 h after emergence of symptoms of a disease.

The adult in the first day appoint 100 mg of 3 times/days; in the second and third days on 100 mg of 2 times/days; in the fourth and fifth day on 100 mg of 1 times/days. In the first day of a disease drug use once in a dose of 300 mg is possible.

To children aged from 7 up to 10 years appoint 50 mg of 2 times/days; from 11 to 14 years - 50 mg of 3 times/days. 14 years - doses for adults are more senior.

Accept within 5 days.

For prevention of flu adult appoint 50 mg of 1 times/days during up to 30 days. To children 7 years - 50 mg of 1 times/days during up to 15 days are more senior.

Features of use:

Use at abnormal liver functions. Drug use is forbidden to patients with acute diseases of a liver.

With care to apply at a liver failure.

Use at renal failures. Drug use is forbidden to patients with acute and chronic diseases of kidneys.

Use for children. Drug use is forbidden to children 7 years are younger.

Use for elderly patients. At elderly people drug can collect in toxic concentration if the dose is not adjusted in proportion to reduction of KK.

At use of Rimantadinum the exacerbation of chronic associated diseases is possible. At patients of advanced age with arterial hypertension the risk of development of a hemorrhagic stroke increases.

At instructions in the anamnesis on epilepsy and the carried-out anticonvulsant therapy against the background of use of Rimantadinum the risk of development of an epileptic seizure increases. In such cases Rimantadinum apply in a dose 100 mg/days along with anticonvulsant therapy.

At the flu caused by a virus B, Rimantadinum has anti-toxic effect.

Preventive reception is effective at contacts with the diseased, at spread of an infection in the closed collectives and at high risk of developing of a disease during a flu epidemic.

Emergence of viruses, resistant to drug, is possible.

During treatment it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

From the alimentary system: dryness in a mouth, nausea, vomiting, loss of appetite, pain in epigastriums, a meteorism.

From TsNS: headache, dizziness, sleeplessness, neurologic reactions, disturbance of concentration of attention, drowsiness, uneasiness, hypererethism, fatigue.

Others: hyperbilirubinemia, allergic reactions (skin rash, itch, small tortoiseshell).

Interaction with other medicines:

Rimantadinum reduces efficiency of antiepileptic drugs.

Paracetamol and ascorbic acid reduce the maximum concentration of Rimantadinum in a blood plasma by 11%.

Cimetidinum reduces clearance of Rimantadinum by 18%.

The adsorbents knitting and enveloping means reduce absorption of Rimantadinum.

The means alkalinizing urine (acetazoleamide, Natrii hydrocarbonas, etc.) increase efficiency of Rimantadinum owing to reduction of its allocation by kidneys.

Contraindications:

— acute diseases of a liver;

— acute and chronic diseases of kidneys;

— thyrotoxicosis;

— hypersensitivity to Rimantadinum;

— pregnancy and period of a lactation;

— children up to 7 years;

— at a lactose intolerance, a lactose intolerance, a lactose/isomaltose sprue (since lactose is a part of drug).

With care: at arterial hypertension, atherosclerosis of vessels of a brain, a liver failure, epilepsy, gastrointestinal diseases.

Overdose:

Symptoms: excitement, hallucinations, arrhythmia.

Treatment: gastric lavage, symptomatic therapy: actions for maintenance of the vital functions. Rimantadinum is partially removed at a hemodialysis

Storage conditions:

Drug should be stored in dry, protected from light and the place, unavailable to children, at a temperature not above 25 °C. Period of validity of 5 years.

Issue conditions:

Without recipe

Packaging:

10 pieces - planimetric strip packagings (2) - packs cardboard.
20 pieces - planimetric strip packagings (1) - packs cardboard.
20 pieces - banks polymeric (1) - packs cardboard.